Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
80 participants
INTERVENTIONAL
2022-06-01
2023-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis
NCT05432531
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus
NCT03616912
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
NCT02708095
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
NCT03843125
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)
NCT03616964
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Baricetinib 4 mg
4 mg oral tablet daily
Baricitinib 4 MG
4 mg oral daily
Baricetinib 2 mg
2 mg oral tablet daily
Baricitinib 2 MG
2 mg oral daily
MMF
MMF 500 mg tablet twice daily
MMF
1000 mg oral daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Baricitinib 4 MG
4 mg oral daily
Baricitinib 2 MG
2 mg oral daily
MMF
1000 mg oral daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be able to swallow tablets
* lupus nephritis in remission
Exclusion Criteria
* thrombosis history
* sever anemia, leukopenia or thrombocytopenia
* impaired liver and renal function
20 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Manal Hassanien
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Manal Hassanien, MD
Role: PRINCIPAL_INVESTIGATOR
Assiut University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Manal Hassanien
Asyut, Yes, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
systemic lupus
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.